Navigating a Power Outage When You’re on an Oxygen Concentrator

DWN12088 Fares Well in Study of Healthy Volunteers

DWN12088, an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase 1 clinical trial that enrolled healthy volunteers. Daewoong Pharmaceutical, the therapy’s developer, now plans to start a Phase 2 trial later this year. “We…

Inhaled Pirfenidone Prevented Lung Function Decline in IPF

High-dose AP01 (inhaled pirfenidone) largely prevented lung function decline and was safe and well-tolerated during the first 24 weeks of a Phase 1/2 clinical study testing its use in patients with idiopathic pulmonary fibrosis (IPF). Avalyn Pharma, the therapy’s developer, presented the results at the 2021…

Changes in Blood Cell Ratios Linked to Worse Outcomes

Idiopathic pulmonary fibrosis (IPF) patients showing greater changes in blood cell ratios often used as markers of inflammation are at higher risk of lung function decline, respiratory hospitalization, and death, according to a post-hoc analysis of data from several Phase 3 clinical trials. Notably, these associations were more pronounced…

The Power of PF Storytelling, and a Plea for Change

Stories have been a catalyst for conversation for centuries. Generations of families are often weaved together by the narrative of a loved one’s past, and by the stories that have shaped our evolution. There is so much to learn through the stories of those who came before us. As a…

‘Stay Strong and Never Hide Your Illness’

I will celebrate my two-year diagnosis anniversary on Dec. 11. On this day, which changed my life forever, I was finally diagnosed with lymphocytic interstitial pneumonia. My head was spinning when I heard these words. What is this illness? I wondered. Is it curable? It must be curable, I…